Diffuse Alveolar Hemorrhage clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
open to eligible people ages up to 24 years
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic…
at UCSF
Our lead scientists for Diffuse Alveolar Hemorrhage research studies include Gabriel Salinas Cisneros, MD.
Last updated: